Evolus
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 273
- Market Cap
- $1B
- Website
- http://www.evolus.com
- Introduction
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.
Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Recruiting
- Conditions
- Glabellar Frown Lines
- Interventions
- Drug: prabotulinumtoxinA
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 750
- Registration Number
- NCT05481931
- Locations
- 🇩🇪
Cologne Dermatology, Cologne, Germany
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
Phase 2
Completed
- Conditions
- Glabellar Frown Lines
- Interventions
- Drug: PrabotulinumtoxinA-XvfsDrug: OnabotulinumtoxinA
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT05320393
- Locations
- 🇺🇸
Aesthetic Eyelid Plastic Surgery, Boca Raton, Florida, United States
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
Phase 2
Completed
- Conditions
- Glabellar Frown Lines
- Interventions
- Biological: DWP-450 (Botulinum purified neurotoxin, Type A)
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 570
- Registration Number
- NCT02428608
- Locations
- 🇺🇸
The Advanced Skin Research Center at Skin Specialists, PC, Omaha, Nebraska, United States
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
Phase 3
Completed
- Conditions
- Glabellar Frown Lines
- Interventions
- Biological: Botulinum toxin, Type AOther: 0.9% sterile, unpreserved saline
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 324
- Registration Number
- NCT02334436
- Locations
- 🇺🇸
The Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
Phase 3
Completed
- Conditions
- Glabellar Frown Lines
- Interventions
- Other: 0.9% sterile, unpreserved salineBiological: Botulinum toxin, Type A
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT02334423
- Locations
- 🇺🇸
Steven Fagien, MD, Boca Raton, Florida, United States
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
Phase 2
Completed
- Conditions
- Glabellar Frown Lines
- Interventions
- Biological: Botulinum purified neurotoxin, Type A
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Evolus, Inc.
- Target Recruit Count
- 352
- Registration Number
- NCT02184988
- Locations
- 🇺🇸
ATS Clinical Research, Santa Monica, California, United States
© Copyright 2025. All Rights Reserved by MedPath